Class II Medical Device Z-2937-2026 Ongoing

An unvalidated reprocessing step had been in use — 23 device records turn on validation (malaria test kits)

Bioporto Diagnostics A/S Reported Aug 19, 2026

A non-validated rework process was used on assay reagents in an in-vitro diagnostic (IVD) kit for acute kidney injury. This could lead to missed diagnosis of renal disease, inappropriate treatment decisions, or inappropriate monitoring. The recall covers 400 units distributed to the United States, the European Union, Chile and Hong Kong.

Recall overview (primary data)

  • ClassificationClass II
  • Product typeMedical Device
  • Recalling firmBioporto Diagnostics A/S
  • ReasonThe use of a non-validated rework process for assay reagents which could lead to missed diagnosis of renal disease, inappropriate treatment decisions, or inappropriate monitoring of renal disease in intended users.
  • DistributionWorldwide - The affected product distribution included the United States and the countries of European Union, Chile, and Hong Kong. No affected product was distributed to Canada; however, Health Canad...
  • Recall initiated2026-05-18

Key points

  • The product is the ProNephro AKI (NGAL) Reagent Kit of 100 tests — 400 units. It is an in-vitro diagnostic test system for acute kidney injury.
  • The reason is the use of a non-validated rework process for assay reagents; the ground is not that values drifted but that the product left the range in which performance is assured.
  • It could lead to missed diagnosis of renal disease, inappropriate treatment decisions, or inappropriate monitoring.
  • Distributed to the United States, the European Union, Chile and Hong Kong. No product went to Canada, but Health Canada was notified because the product is registered there.
  • Of the 1,408 recall records this site holds as of 2026-08-28, 1,392 — 98.9 percent — were firm-initiated, and only 8 were FDA mandated.
  • Of the 779 device records this site holds as of 2026-09-01, 23 name validation in the reason.

1When it is the test itself that goes wrong

Most device recalls concern the part that touches the patient: something breaks, leaks, or loses sterility. An in-vitro diagnostic reagent kit is different. Nothing enters the body; what comes out is a number. If that number is off, a disease that is present goes unseen and the treatment that was needed does not start.

The outcomes the record lists — missed diagnosis, inappropriate treatment decisions, inappropriate monitoring — all follow from trusting the number.

2The phrasing is that the rework was not validated

The reason does not say the rework process itself was wrong. It says a non-validated rework process was used. In manufacturing, taking intermediate material that fell outside specification and bringing it back into a usable state is not unusual in itself. What is required is confirming in advance that the procedure does not compromise product performance.

Product put through an unconfirmed procedure sits outside the range in which performance is assured. The ground for recall is not that the values did drift but that they left the assured range at all.

398.9 percent of recalls begin with the firm

Of the 1,408 FDA recall records this site holds as of 2026-08-28, 1,39298.9 percent — were initiated by the firm, and only 8 were FDA mandated. This one is firm-initiated, and the record notes that although no affected product went to Canada, Health Canada was notified because the product is registered there.

What the distribution shows is that the recall system runs on disclosure by companies rather than on enforcement by the regulator. Whether any erroneous test result was actually produced is not part of this record.

4Twenty-three device records turn on validation

Of the 779 device records this site holds as of 2026-09-01, 23 name validation in the reason for recall.

Device records naming validation23 / 779

The fault found is not in the product but in the absence of the procedure that confirms a process is sound. Whether the results were correct remains unknown, and without having checked, no-one can call it sound either. On a product whose output feeds a diagnosis, as a test kit does, that uncertainty is itself the reason for recall.

Why it matters

A faulty test kit, unlike a broken instrument, is invisible on the floor: a number comes back, so there is little to prompt doubt. That is precisely why a validated manufacturing process is the substance of quality, and why putting product through an unconfirmed procedure is itself sufficient ground for recall.

FAQ

What does in-vitro diagnostic mean?
A product used to examine a collected specimen outside the body rather than inside the patient. It never touches the patient, but the number it returns drives diagnosis and treatment.
Is the rework itself the problem?
No. What the record identifies is the use of a non-validated rework process — meaning it had not been confirmed in advance that the procedure does not compromise product performance.
Were erroneous results actually produced?
That is not part of this record. What is stated goes as far as the outcomes considered possible, such as missed diagnosis and inappropriate treatment decisions.

Sources (primary)

Source: openFDA (U.S. FDA, CC0 public domain). Data is provided as-is and must not be used for medical decisions. Verify the latest and exact details with the official FDA recall information. This site is not endorsed or certified by the U.S. FDA.

#FDA#Recall#Medical devices#In-vitro diagnostics#Kidney
Disclaimer: This site independently summarizes and classifies information based on official data sources. Always verify the latest and accurate information with the official sources. Content on finance, health, legal, and security is information, not advice. This site is not an official website of the U.S. government.